ѻý

Dementia Tied to Olfaction; Preclinical Alzheimer's Trial; Guillain-Barré and COVID-19

<ѻý class="mpt-content-deck">— News and commentary from the world of neurology and neuroscience
MedpageToday
Brain scan images with NeuroBreak in the center.

Older adults who had even moderate , especially sense of smell, had a higher risk of dementia, researchers reported in Alzheimer's & Dementia.

Certain cardiovascular risk factors, especially hypertension, diabetes, and smoking were tied to increased risk of . (Neurology)

Adjunctive rotigotine (Neupro), a dopaminergic agonist used in Parkinson's disease, showed no effect on memory and other cognitive tasks in Alzheimer's patients, but and reduced functional impairment, a phase II trial showed. (JAMA Network Open)

Patients diagnosed with compared with the general population. (Neurology)

AHEAD 3-45, a phase III trial of the anti-amyloid drug BAN2401 in , is underway in the U.S., Eisai and Biogen announced.

Half of adults with spinal muscular atrophy type 2 or 3 in a small, single-center study reported (Spinraza) over 2 years, but none showed significant objective changes. (Neurology)

Visual impairment was than in the general population and was tied to depression, anxiety, and dementia. (Movement Disorders)

Parkinson's disease is estimated to affect with a total economic burden approaching $80 billion by 2037... (npj Parkinson's Disease)

...which may be related, in part, to increased , researchers argue in their book, Ending Parkinson's Disease. (New York Times)

More than after the multiple sclerosis drug glatiramer acetate (Copaxone) transitioned to a new version was associated with $4.3-$6.5 billion in excess spending. (JAMA Internal Medicine)

AbobotulinumtoxinA (Dysport) received in pediatric patients with cerebral palsy, drugmaker Ipsen said.

About one-third of people with Alzheimer's disease and related dementias could , according to an online caregiver survey. (JAMA Network Open)

Concentrations of plasma p-tau181 were with familial Alzheimer's disease, raising the possibility it could be an easily accessible Alzheimer's biomarker. (Molecular Psychiatry)

Is ? Some neurologists aim to find out. (Newsweek)

  • Judy George covers neurology and neuroscience news for ѻý, writing about brain aging, Alzheimer’s, dementia, MS, rare diseases, epilepsy, autism, headache, stroke, Parkinson’s, ALS, concussion, CTE, sleep, pain, and more.